Table 2:
Baseline demographics of severe psoriasis cohort compared to healthy volunteers.
| Parameter | Severe Psoriasis (N = 30) |
Healthy Volunteers (N = 47) |
p- value |
|---|---|---|---|
| Demographics and medical history | |||
| Age, years | 51.1 ± 12.0 | 40.3 ± 12.2 | <0.001 |
| Males | 23 (77%) | 37 (79%) | 0.83 |
| Hypertension | 11 (37%) | 7 (15%) | 0.03 |
| Hyperlipidemia | 15 (50%) | 14 (30%) | 0.07 |
| Type 2 diabetes mellitus | 4 (13%) | 3 (6%) | 0.30 |
| Current tobacco use | 3 (10%) | 0 (0%) | 0.03 |
| Lipid treatment | 11 (37%) | 7 (15%) | 0.06 |
| Body mass index | 30.3 ± 7.2 | 27.1 ± 4.8 | 0.02 |
| Waist-to-hip ratio | 0.99 (0.95 - 1.05) | 0.95 (0.89 - 1.00) | 0.02 |
| Clinical and laboratory values | |||
| Systolic blood pressure, mm Hg | 122.9 ± 15.6 | 114.8 ± 12.2 | 0.01 |
| Diastolic blood pressure, mm Hg | 73.8 ± 10.5 | 70.0 ± 8.3 | 0.08 |
| Total cholesterol, mg/dL | 172.8 ± 36.0 | 183.4 ± 38.1 | 0.23 |
| HDL cholesterol, mg/dL | 51.9 ± 15.2 | 55.6 ± 18.1 | 0.36 |
| LDL cholesterol, mg/dL | 100.5 ± 32.4 | 102.7 ± 32.8 | 0. 78 |
| Triglycerides, mg/dL | 119.8 ± 75.3 | 126.2 ± 99.0 | 0.77 |
| Framingham risk score | 3.5 (1.0 – 6.0) | 1.3 (0.4 – 3. 9) | 0.004 |
| C-reactive protein, mg/L | 3.0 (1.6 – 8.7) | 1.1 (0.7 - 2.6) | 0.001 |
| HOMA-IR* | 3.5 (1.6 – 5.3) | 2.3 (1.6 – 3.4) | 0.03 |
| Cholesterol efflux capacity | 0.89 ± 0.14 | 1.00 ± 0.16 | 0.006 |
| Psoriasis characterization | |||
| Psoriasis area severity index score | 15.5 (12.5 – 23.2) | - | - |
| Total body surface area index | 28.1 (20.2 – 43.5) | - | - |
| Systemic or biologic treatment | 9 (30%) | - | - |
| Amygdalar activity(18FDGPET/CT) | |||
| Amygdalar FDG uptake | 1.12 ± 0.11 | 1.06 ± 0.12 | 0.02 |
| Aortic vascular inflammation(18FDG PET/CT) | |||
| Target-to-background ratio | 1.78 ± 0.32 | 1.62 ± 0.20 | 0.02 |
| Coronary plaque burdens (x100) | |||
| Total burden, mm2 | 1.37 ± 0.73 | 1.05 ± 0.33 | <0.001 |
| Non-calcified burden, mm2 | 1.29 ± 0.69 | 1.04 ± 0.34 | <0.001 |
| Hematopoietic system activity(18FDG PET/CT) | |||
| Bone marrow (SUV† max) | 4.05 ± 1.15 | 3.52 ± 0.96 | 0.03 |
| Spleen (SUV† max) | 3.55 ± 1.03 | 3.32 ± 0.83 | 0.29 |
Values reported in the table as Mean ± SD or Median (IQR) for continuous data and N (%) for categorical data. P-value ≤ 0.05 deemed significant. P-values were calculated by using student’s t-test or Mann-Whitney U test for continuous variables and Pearson’s chi-squared test for categorical variables.
*
HOMA-IR: Homeostasis model assessment of insulin resistance.
†
SUV: Standardized uptake value.